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(ACCESSATION)
Peter Selby1,2,3*†, Gerald Brosky4†, Paul Oh5†, Vincent Raymond6†, Carmen Arteaga7† and Suzanne Ranger8†Abstract
Background: Many smokers find the cost of smoking cessation medications a barrier. Financial coverage for these
medications increases utilization of pharmacotherapies. This study assesses whether financial coverage increases the
proportion of successful quitters.
Methods: A pragmatic, open-label, randomized, controlled trial was conducted in 58 Canadian sites between March
2009 and September 2010. Smokers (≥10 cigarettes/day) without insurance coverage who were motivated to quit
within 14 days were randomized (1:1) in a blinded manner to receive either full coverage eligibility for 26 weeks or
no coverage. Pharmacotherapies covered were varenicline, bupropion, or nicotine patches/gum. Investigators/subjects
were unblinded to study group assignment after randomization and prior to choosing a smoking cessation method(s).
All subjects received brief smoking cessation counseling. The primary outcome measure was self-reported 7-day point
prevalence of abstinence (PPA) at week 26.
Results: Of the 1380 randomized subjects (coverage, 696; no coverage, 684), 682 (98.0%) and 435 (63.6%), respectively,
were dispensed at least one smoking cessation medication dose. The 7-day PPA at week 26 was higher in the full
coverage versus no coverage group: 20.8% (n = 145) and 13.9% (n = 95), respectively; odds ratio (OR) = 1.64, 95%
confidence interval (CI) 1.23–2.18; p = 0.001. Urine cotinine-confirmed 7-day PPA at week 26 was 15.7% (n = 109)
and 10.1% (n = 69), respectively; OR = 1.68, 95% CI 1.21–2.33; p = 0.002. After pharmacotherapy, coverage eligibility
was withdrawn from the full coverage group, continuous abstinence between weeks 26 and 52 was 6.6% (n = 46)
and 5.6% (n = 38), in the full coverage and no coverage groups, respectively; OR = 1.19, 95% CI 0.76–1.87; p = 0.439.
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Conclusions: In this study, the adoption of a smoking cessation medication coverage drug policy was an effective
intervention to improve 26-week quit rates in Canada. The advantages were lost once coverage was discontinued.
Further study is required on the duration of coverage to prevent relapse to smoking. (clinicaltrials.gov identifier:
NCT00818207; the study was sponsored by Pfizer Inc.).
Keywords: Bupropion, Clinical trial, Medications, Nicotine, Pharmacotherapy coverage, Policy, Pragmatic,
Reimbursement, Smoking cessation, VareniclineBackground
Tobacco addiction is associated with one in eight deaths
worldwide [1]. The efficacy of all smoking cessation medi-
cations (pharmacotherapy) i.e., varenicline, bupropion, and
nicotine replacement therapies (NRTs; patch, gum, lozenge,
inhaler, and nasal spray) is well established [2-6]. Nicotine
replacement therapies (odds ratio [OR] = 1.89, credible
interval [CrI] 95% 1.63–2.18), bupropion (OR = 1.95,
CrI 95% 1.58–2.41), and varenicline (OR = 2.78, CrI 95%
2.17–3.57) all increase the odds of 12-month abstinence
compared with placebo [5]. Although there are many
reasons why smokers do not access pharmacotherapy,
lack of insurance coverage remains a significant barrier
[7]. Pharmacotherapy coverage may increase the number of
quit attempts, the likelihood of pharmacotherapy utilization
and adherence, and ultimately, smoking cessation.
Despite pharmacotherapies being among the most cost-
effective and highly advocated interventions for coverage
[8], funders have been slow to invest. Systematic reviews
concluded that full coverage (versus no coverage) of
pharmacotherapies could increase quit rates with low
attributable incremental cost [5,9]. However, the included
trials typically excluded real-world smokers who often
have psychiatric and medical comorbidity, thereby limiting
generalizability [10]. The few published pragmatic studies
have several methodological problems such as not being
randomized controlled trials (RCTs) and not including all
available pharmacotherapies [9].
Based on the 10 dimensions of the PRECIS Tool to
evaluate clinical trial design [11,12], this mostly pragmatic
open-label RCT evaluated the effectiveness of pharmaco-
therapy coverage versus no coverage for 26 continuous
weeks in increasing smoking cessation in ambulatory care
settings in motivated adult smokers in Canada.Methods
Study design and participants
This open-label RCT was conducted in 58 different sites
across Canada (excepting Quebec, Alberta, and New
Brunswick). Smokers were recruited by study site referrals
and advertisement. Potential subjects were screened by a
call centre to assess initial eligibility and drug insurance
coverage. The investigator then confirmed eligibility
(see Additional file 1).Participants were adults (18–75 years) who smoked
≥10 cigarettes per day, were willing to set a quit date
within 14 days following screening/randomization, had
no period of abstinence >3 months in the past year, and
had not attempted to quit smoking in the 30-day period
before screening. Exclusion criteria were: unknown
insurance status, access to unused pharmacotherapy or
prescription, use of tobacco products other than cigarettes
within the past month, and life-threatening illness (e.g.,
known or suspected cancer or other disease with a life
expectancy of <1 year). Medical and psychiatric conditions
were not exclusion criteria per se.
The study was conducted in compliance with the ethical
principles originating in or derived from the Declaration
of Helsinki and in compliance with all International
Conference on Harmonization Good Clinical Practice
Guidelines. Written informed consent for participation in
the study was obtained from all participants. The final
protocol, any amendments, and informed consent docu-
mentation were reviewed and approved by the Canadian
Institutional Review Board (IRB) (IRB Services, Aurora,
ON, Canada), or by local Canadian Ethics Committees
(University of British Columbia Clinical Research Ethics
Board, Vancouver, BC; Vancouver Island Health Authority
Clinical Research Ethics Board, Victoria, BC; University
of Manitoba Research Ethics, Winnipeg, MB; Winnipeg
Clinic Ethics Committee, Winnipeg, MB; Research Ethics
Board St. Joseph's Healthcare Hamilton, Hamilton, ON;
University of Western Ontario Office of Research Ethics,
London, ON).Randomization and interventions
Eligible participants were first counseled about smoking
cessation and then randomly and blindly assigned (1:1;
centrally to prevent gaming) at the baseline visit to
receive either full coverage for 26 weeks or no coverage.
Randomization was performed by the investigators using
blinded lots of computer-generated randomization codes
from the study biostatistician. Randomization codes were
mapped to SmartPayment™ cards (drug reimbursement
cards), with a distinctive color linked to the study arm to
which the subject was randomized. The SmartPayment™
cards were enclosed in sealed envelopes with the
randomization codes printed on the envelopes. After
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pharmacological and/or non-pharmacological smoking
cessation method(s) to be used. Eligible pharmacotherapies
were: varenicline; bupropion; and NRT patch and gum,
prescribed according to the most recent version of the
respective product monograph or equivalent (see Additional
file 2). A prescription had to be issued by a physician for
these pharmacotherapies to be reimbursed; NRTs obtained
without a prescription were not eligible for coverage, but
were considered medication for statistical analysis. Partici-
pants (irrespective of allocated group) were not obliged to
use a pharmacotherapy in their quit attempt. A target quit
date was set within 14 days of randomization. The use
of a SmartPayment™ card permitted access to either full
coverage of prescribed pharmacotherapy for 26 weeks
(full coverage) or a reimbursement of $5.00 per pharmacy
dispensation (no coverage). This facilitated tracking of
prescriptions dispensed in both groups and provided an
incentive for subjects in the no coverage group to present
their card at each pharmacy visit. Participants received
compensation for reasonable expenses for transportation
or parking for study appointments, if needed.
Assessments and follow-up
Patient assessment, treatment recommendations, and
prescriptions, as needed, were performed by physicians.
Other study-related tasks were performed by trained
personnel. Participants were screened at the baseline
visit for demographic information, type of drug plan
insurance, smoking history, Fagerström Test for Nicotine
Dependence (FTND) score [13,14], comorbid medical/
psychiatric history including the Columbia Suicide Severity
Rating Scale (C–SSRS [15]), and concomitant medications.
Brief (10-minute) smoking cessation counseling was
provided to all subjects at the screening visit and at
each contact, per each site’s practice. Prior to study
start, all participating sites were provided brief training
in current clinical recommendations/guidelines [16].
Participants made four clinic visits (weeks 1, 26, 39,
and 52), and received six telephone calls (weeks 2, 13,
30, 34, 44, and 48), during which smoking status, quit
attempt(s)/methods, FTND score, and abstinence status
(via self-report at clinic visits) were collected. Confirma-
tory urinary cotinine measurements were collected, but
investigators and patients were blinded to the results to
mimic real-world practice (where this is not widely used).
Patients were not aware that physicians were blinded to
the results.
Safety evaluations included adverse event (AE)
monitoring, physical examinations, and C–SSRS [15].
All observed or volunteered AEs, regardless of smok-
ing cessation method or suspected causal relationship,
were to be reported. The investigator was required to
pursue information to both determine the outcome ofthe AE and assess whether it met criteria for a serious
AE. Events were recorded up to and including 28 days
after the last administration of one of the smoking
cessation methods or week 26 (whichever was longer).
Effectiveness evaluations
The primary endpoint was self-reported 7-day point
prevalence of abstinence (PPA) at week 26 (end of
coverage eligibility), defined as abstinence from smoking
(not a single puff ) for at least the preceding 7 days
[17]. This pragmatic endpoint was chosen because in
real-world settings there is no evidence of significant
difference between estimates of smoking prevalence
based on self-report versus urinary cotinine measure [18].
Whereas the primary endpoint was more pragmatic,
the key secondary endpoints (self-reported 7-day PPA
at week 26 and continuous abstinence rates [CAR] at
weeks 26–52, confirmed by urine cotinine) were more
explanatory. Other secondary endpoints were self-reported
7-day PPA at weeks 2 and 13, self-reported CAR (weeks
26–39), total number of quit attempts from randomization
through week 26, and use of smoking cessation pharmaco-
therapies during quit attempts.
Statistical analysis
Based on previous clinical studies of varenicline [19,20],
market research, and relevant literature [21-24], quit
rates in the no coverage versus full coverage group were
assumed to be 15% versus 21%, respectively. A sample
size of at least 676 participants per group was estimated
to provide 80% power to detect a conservative difference
of 6% between groups. Some consider a 2% difference
clinically significant because of the estimated 50% risk
reduction in smoking-related mortality associated with
cessation [25]. Outcome measures were assessed using
an intent-to-treat (ITT) analysis that included all ran-
domized participants. Individuals who discontinued the
study or were lost to follow-up were counted as smokers
from the time of discontinuation. For calculation of CAR,
participants who reported no smoking or no use of
nicotine since the last contact and had a negative urine
cotinine test were counted as non-smokers. Participants
with missing urine cotinine test results were considered
smokers.
Endpoints were analyzed using logistic regression models
that included randomized group effect (full coverage
versus non-coverage) as the independent variable and
investigation centre as a covariate. In addition, the inter-
action between randomized group and centre was tested
by expanding the logistic regression model to add the
interaction term. In testing for the primary and key
secondary endpoints, the Type-I overall error rate of
0.05 was preserved by using statistical methods that
adjusted for multiple tests.
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subjects. The incidence of AEs reported during the
study was summarized by randomized arm (coverage;
non-coverage) and pharmacotherapy (users; non-users)
for descriptive rather than comparative purposes.
Results
Baseline characteristics
Eligible participants were recruited from March 3, 2009 to
September 20, 2010. Participants attended clinic visits at the
time of randomization and at regular intervals for 52 weeks.
Using postal codes as a proxy, participating sites were iden-
tified as being both in urban (54) and rural (4) locations.
Participants were recruited by eight specialists (n = 115;
8.3%) and 50 generalists (n = 1265; 91.7%) and were referred
from clinical practice (n = 1289; 93.4%) or advertisement
(n = 91; 6.6%). Participant disposition is summarized in
Figure 1. Baseline demographics, smoking history, and
level of nicotine dependence were well balanced (Table 1).
Interactions for randomization group by centre were not
statistically significant (p > 0.4), supporting the consistency
of using combined results from different centres. The
primary analysis was ITT and involved all patients who
were randomly assigned (696 subjects in the full coverage
group and 684 subjects in the no coverage group).
Participants were analysed by original group assignment.
Effectiveness of coverage of pharmacotherapy
Significantly more participants in the full coverage versus
no coverage group achieved the primary endpoint ofReceived allocated intervention: n = 696 (100%)
Smoking cessation pharmacotherapy users = 682 (98.0%)
n = 222 (31.9%)
Subject died
6 = nsEA
Lost to follow-up n = 160









Completed study: 474 (68.1%)
Figure 1 Participant disposition [26].7-day PPA at week 26 (20.8% versus 13.9%, respectively;
odds ratio (OR) = 1.64, 95% confidence interval (CI)
1.23–2.18; p = 0.001; Table 2). Significant differences in
7-day PPA between the full coverage and no coverage
groups were observed at week 2 (18.8% versus 13.3%;
p = 0.003) and at week 13 (34.1% versus 23.7%; p < 0.001).
The difference remained significant for urine cotinine-
confirmed 7-day PPA at week 26 (15.7% versus 10.1%,
respectively; OR = 1.68, 95% CI 1.21–2.33; p = 0.002;
Table 2). After withdrawal of coverage eligibility, there
was no significant difference in CAR from weeks 26 to
52 between the two groups (week 52, n = 6.6% versus
n = 5.6%, respectively; OR = 1.19, 95% CI 0.76–1.87;
p = 0.439; see Additional file 3). Similar results were noted
at week 39 (7.8% versus 6.3%, respectively; OR = 1.25,
95% CI 0.82–1.90; p = 0.298). However, 7-day PPA data
were not collected after 26 weeks and the CAR at weeks
26–52 should not be directly compared with 7-day PPA
data. A post-hoc analysis showed that pharmacotherapy
utilization peaked at week 2 (~90% in the full coverage
group), after which it steadily decreased for the remainder
of the intervention phase, reaching approximately 20% at
week 26 (see Additional file 4).
During the 26-week coverage eligibility period, a higher
proportion of participants in the full coverage versus no
coverage group made at least one quit attempt (86.9%
versus 70.0%, respectively; p < 0.001), but the number of
quit attempts were not statistically different across groups
(mean 3.1 versus 2.6, respectively; p = 0.103), and more
subjects were dispensed at least one pharmacotherapyReceived allocated intervention: n = 684 (100%)
Smoking cessation pharmacotherapy users = 435 (63.6%)
N = 1561
 = 1389
Excluded: n = 9 






Lost to follow-up n = 146




Completed study: 417 (61.0%) 






Age, mean, years (SD) 46.5 (12.3) 46.7 (12.3)
Gender, n (%)
Male 354 (50.9) 337 (49.3)
Female 342 (49.1) 347 (50.7)
Race, n (%)
White 664 (95.4) 660 (96.5)
Black 11 (1.6) 6 (0.9)
Asian 15 (2.2) 13 (1.9)
Other 6 (0.9) 5 (0.7)
Educational level, years, n (%)
<10 46 (6.6) 57 (8.3)
10–12 321 (46.1) 305 (44.6)
13–16 273 (39.2) 257 (37.6)
>16 56 (8.0) 61 (8.9)
Employment status, n (%)
Full-time employed 298 (42.8) 297 (43.4)
Part-time employed 79 (11.4) 77 (11.3)
Not employed 319 (45.8) 308 (45.0)
Insurance type, n (%)
Private insurance 51 (7.3) 53 (7.7)
Government-provided
insurance
143 (20.5) 137 (20.0)
No drug insurance 484 (69.5) 479 (70.0)
Other type of insurance 18 (2.6) 14 (2.0)
Household income, n (%)
<$15,000 CAD 58 (8.3) 92 (9.1)
$15,000– <$25,000 CAD 260 (37.4) 246 (36.0)
$25,000– <$50,000 CAD 203 (29.2) 218 (31.9)
$50,000– <$75,000 CAD 78 (11.2) 62 (9.1)
$75,000– <$100,000 CAD 32 (4.6) 31 (4.5)
>$100,000 CAD 22 (3.2) 17 (2.5)
Body mass index (kg/m2),
mean (SD)
28.1 (6.3) 28.3 (6.5)
Smoking history
Age at onset of smoking,
years, mean (SD)
15.5 (4.5) 15.5 (4.0)
Cigarette pack years, mean (SD) 34.8 (21.8) 34.6 (21.5)
Cigarettes/day (past month),
mean (range)
22.2 (9.5) 21.5 (8.3)
FTND score, mean (SD)* 5.9 (2.1) 5.9 (2.1)
Number of lifetime serious quit
attempts – any method, n (%)
0 93 (13.4) 64 (9.4)
1 163 (23.4) 166 (24.3)
Table 1 Baseline characteristics of study participants
(Continued)
2 143 (20.5) 148 (21.6)
≥3 297 (42.7) 306 (44.7)
Comorbidities†
COPD 65 (9.3) 77 (11.3)
Lung cancer 0 2 (0.3)
Coronary heart disease 18 (2.6) 17 (2.5)
Stroke 1 (0.1) 2 (0.3)
Asthma exacerbation 76 (10.9) 66 (9.6)
Past psychiatric disorder 73 (10.5) 65 (9.5)
Current psychiatric disorder 230 (33) 213 (31.1)
Current depression 109 (15.7) 106 (15.5)
Current anxiety/anxiety disorder 66 (9.5) 61 (9.0)
CAD = Canadian dollar; COPD = chronic obstructive pulmonary disease;
FTND = Fagerström Test for Nicotine Dependence; SD = standard deviation;
SES = socioeconomic status.
*Scores range from 0 to 10, with higher scores indicating greater nicotine
dependence. †Comorbidities reported as “present” in subjects’ medical history
at the time of the screening/randomization visit.
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number of daily doses dispensed per participant was
higher in the full versus no coverage group, except for
bupropion (70 versus 42, respectively; p < 0.001, for
varenicline; 56 versus 18.5; p < 0.001, respectively, for NRTs;
and 39 versus 34; p = 0.454, respectively, for bupropion).
In the full coverage group, varenicline was dispensed
at least once for 558 participants (80.2%), nicotine
patches/gum for 201 participants (28.9%), and bupropion
for 60 (8.6%) participants. The corresponding figures for
the no coverage group were 297 (43.4%), 126 (18.4%), and
58 (8.5%). In the full coverage group, 18.4% of participants
used at least two distinct pharmacotherapies, whereas only
6.3% did so in the no coverage group. Non-pharmacological
methods were used by 5.7% and 9.9%, respectively.Adverse events
Adverse events are listed in Table 3. Serious AEs consid-
ered by the investigator to be treatment-related were
reported for two participants in the full coverage group
(muscular weakness and hyperkalemia; both n = 1) and
two in the no coverage group (violence-related symptom
and depression; both n = 1). Results from the C–SSRS
assessment were also similar between the groups and
revealed a “yes” answer for suicidal ideation and/or
behavior in 25 (3.7%) and 11 (2.5%) in the full coverage
and no coverage groups, respectively. A suicidal attempt
was reported in one subject who did not take pharmaco-
therapy. All-causality AEs reported for ≥5% of participants
(randomized and used smoking cessation pharmacotherapy)
in the full coverage and no coverage arms, respectively,
Table 2 7-day point prevalence of abstinence from weeks 2 to 26 and complete abstinence rate from weeks 26 to 52
(intent-to-treat)
Full coverage (n = 696),
proportion of patients, %
No coverage (n = 684),
proportion of patients, %
OR (95% CI) p-value
7-day PPA
Week 2 18.8 13.3 1.59 (1.17–2.16) 0.003
Week 13 34.1 23.7 1.72 (1.35–2.20) <0.001
Week 26 20.8 13.9 1.64 (1.23–2.18) 0.001
Week 26 (urine cotinine-confirmed) 15.7 10.1 1.68 (1.21–2.33) 0.002
CAR weeks 26–52 6.6 5.6 1.19 (0.76–1.87) 0.439
CI = confidence interval; CAR = complete abstinence rate; OR = odds ratio; PPA = point prevalence of abstinence.
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45 (6.6%) and 23 (5.3%); insomnia, 41 (6.0%) and 25 (5.7%);
and nausea, 107 (15.7%) and 49 (11.3%).
Discussion
This is the first large-scale, pragmatic, adequately
powered RCT conducted in Canadian ambulatory settings
demonstrating that coverage of recommended pharmaco-
therapies for smoking cessation in motivated smokers
significantly increases quit rates at weeks 2, 13, and 26.
Using self-report and cotinine-confirmed abstinence
measurements, respectively, the probability of quitting
smoking at the end of the intervention in the full
coverage group was 1.64 and 1.68 times larger than the
probability of quitting in the no coverage group. Although
there was a statistically significant difference betweenTable 3 Reported and observed adverse events* (subjects
randomized smoking and used smoking cessation
medication) and Columbia Suicide Severity Rating Scale
(C-SSRS) assessments†




Total number of AEs 1473 830
Total number of participants
with AEs
451 (66.1) 271 (62.3)
Subjects who discontinued
study due to AE
6 (0.9) 0
Subjects with SAEs 35 (5.1) 18 (4.1)
Subjects with severe AEs 57 (8.4) 32 (7.4)
AE = adverse event; SAE = serious adverse event.
*All observed or volunteered AEs, regardless of smoking cessation method, or
selected or suspected causal relationship, were reported. For all AEs, the
investigator was required to pursue and obtain information adequate both to
determine the outcome of the AE and to assess whether it met the criteria for
classification as a serious AE.
†The C–SSRS was part of the neuropsychiatric section of the medical history at
screening/randomization and was administered to all subjects at given visits
and at the investigator’s discretion to assist with safety reporting and
evaluation of possible suicide-related AEs. A “yes” answer for suicidal ideation
and/or behavior was observed in 25 (3.7%) and 11 (2.5%) in the full coverage
and no coverage groups, respectively (all-randomized and treated population).
A suicidal attempt was reported in one subject who did not take smoking
cessation medication.the self-reported and cotinine-confirmed quit rates,
there was no significant difference between the groups
(data not shown). The weeks 26–39 and weeks 26–52
CARs between the two groups did not differ significantly,
possibly indicating the loss of this benefit upon withdrawal
of pharmacotherapy coverage. Using self-reported 7-day
PPA at week 26, for every 14.4 smokers who receive
pharmacotherapy coverage, there will be one additional
quitter. Of every 8.3 persons covered, one will experience
an AE due to attempting to quit smoking, and of every
111, one will discontinue due to a serious AE. Given
that smoking kills one in two people, the risks of
pharmacotherapy are lower than continuing to smoke.
The results of this study could be explained by greater
medication adherence and utilization in the full coverage
group, and a consequent greater number of quit
attempts. In the no coverage group, the larger loss to
follow-up may reflect real-life experience of smokers
who receive cessation counselling, but do not complete
their quit attempt because of lack of coverage. However,
a higher than anticipated number of subjects (63.6%)
in the control group were dispensed pharmacotherapy
during the intervention period. This could be explained
by higher motivation of the smokers in this trial and the
SmartPayment™ card reimbursement of $5.00 per pharmacy
dispensation in the control group. Moreover, the study
sites, although not based in academic centres, might not
reflect other community ambulatory clinics. These clinics
were selected to participate because of their interest in
treating tobacco addiction and might have been more
diligent in promoting medication to stop smoking,
medication adherence, and restarting medications in
those who failed to quit.
The results of our study are consistent with other
studies [9,24,27]. However, our study had a greater
number of quit attempts, use of pharmacotherapy, and
slightly higher quit rates in both groups. This may
be because our study enrolled motivated smokers
and empowered the practitioner–patient dynamic by
permitting tailoring of pharmacotherapy options during
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age by week 39 (13 weeks after coverage ceased) should
be interpreted with caution because it is not clear if the
diminished quit rates reflect the chronic relapsing
nature of nicotine dependence, the erosion of the inter-
vention effect over time [28], lack of statistical power,
the intensity and frequency of the follow-up, or the
stringency of the definition of a continuous quitter for a
pragmatic, real-world trial. It should be noted that
week-26 PPA was chosen as a pragmatic endpoint [11]
and the study was not powered to detect statistical
significance for CARs.
Despite the study limitations, several strengths should
be highlighted. The study was community-based with
minimal exclusion criteria; the majority of subjects were
treated by their own physician; each smoker could
choose their preferred quit method(s) (pharmacological
and/or non-pharmacological); and subjects received
personalized treatment rather than a standard protocol.
Our study attempted to create a longer window than the
usual 10–12 weeks of standard coverage during which
participants could keep trying to quit and allowed for
a switch to or combination with another medication.
Subject recruitment was completed 5 months ahead of
schedule, indicating the demand for services, easy adoption
of the protocol, and feasibility.
Conclusions
The adoption of a pharmacotherapy coverage drug policy
was shown to be an effective intervention to improve
26-week quit rates in Canada. Medication adherence
needs to be promoted by prescribers to enhance quitting.
Relapse prevention strategies that include preventing and
managing slips through extended behavioural and or
pharmacological interventions or combination medication
might be required for smokers who respond to pharmaco-
therapy but relapse once medication is discontinued.
Further research is needed to establish the actual duration
of coverage required for sustained effects on smoking
cessation.
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